Quick Answer
Translational Development Acquisition Corp. reported Cash and Equivalents of $29.8 thousand for fiscal year 2025.
Translational Development Acquisition Corp. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $29.8K | -93.2% |
| 2024 | $438.2K | +21581.0% |
| 2023 | $2.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $47.1K | — | +33.7% |
| June 30, 2025 | $35.3K | — | -82.9% |
| March 31, 2025 | $206.6K | — | -52.8% |
| December 31, 2024 | $438.2K | — | — |
- Translational Development Acquisition Corp. showed a decrease of -93.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Translational Development Acquisition Corp.’s cash and equivalents has grown by 1373.9% (from $2.0 thousand to $29.8 thousand).
- The most recent figure is from Translational Development Acquisition Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: